Is Atenolol Used for Strokes?
Atenolol is FDA-approved to lower blood pressure in hypertensive patients, which reduces stroke risk as part of primary prevention, but it is not a preferred agent for stroke prevention and should not be used in acute stroke management. 1
Atenolol for Primary Stroke Prevention (Hypertension Treatment)
Atenolol can lower blood pressure and thereby reduce stroke risk in hypertensive patients without prior stroke, but it is inferior to other antihypertensive classes and should not be first-line therapy. 2
Evidence Against Atenolol as First-Line
In the LIFE trial, losartan reduced stroke by 34% compared to atenolol (relative risk 0.66) despite similar blood pressure reductions in hypertensive patients without clinically evident vascular disease, demonstrating that atenolol is less effective than angiotensin receptor blockers for stroke prevention. 3
A 2004 meta-analysis of 17,671 patients showed atenolol was associated with significantly higher all-cause mortality (relative risk 1.13) and more frequent stroke compared to other antihypertensive drugs, despite equivalent blood pressure lowering. 4
Beta-blockers, particularly atenolol, have been shown to be less effective at preventing stroke than other antihypertensive classes in elderly patients, with a 17% increased stroke risk (relative risk 1.17) compared to other agents in patients over 60 years. 5
The 2012 European guidelines note that beta-blockers showed only a 17% stroke reduction versus 29% with other antihypertensive agents in meta-analyses, and atenolol-based treatment was not superior to other regimens in long-term observational studies. 6
Preferred Agents for Primary Prevention
For primary stroke prevention in hypertensive patients, thiazide diuretics, ACE inhibitors, ARBs, or calcium channel blockers are preferred over beta-blockers. 7, 8
The 2024 AHA/ASA Primary Prevention guideline recommends ≥2 antihypertensive medications for most patients requiring pharmacological treatment, with thiazides, ACE inhibitors, and ARBs as foundational agents. 8
Beta-blockers should be reserved for patients with compelling cardiac indications (recent myocardial infarction, heart failure, angina) rather than used as first-line for uncomplicated hypertension. 9, 6
Atenolol in Acute Stroke Management
Atenolol should NOT be used for blood pressure management in acute ischemic stroke or intracerebral hemorrhage.
Acute Ischemic Stroke
In the first 72 hours after acute ischemic stroke, routine blood pressure lowering is not recommended unless systolic BP ≥220 mmHg or diastolic BP ≥120 mmHg, and even then, reduction should be only 10-15% over 24 hours using short-acting IV agents. 7, 9, 10, 11
Oral beta-blockers like atenolol are inappropriate for acute stroke because they lack the rapid onset, short duration, and easy titratability required for safe blood pressure management in the hyperacute phase. 10, 11
For patients receiving IV thrombolysis, blood pressure must be <185/110 mmHg before treatment and maintained <180/105 mmHg for 24 hours using IV labetalol or nicardipine—not oral atenolol. 7, 10, 11
Acute Intracerebral Hemorrhage
One small observational study (n=138) suggested atenolol reduced mortality (11.4% vs 37.3%), SIRS, and pneumonia in hypertensive ICH patients compared to amlodipine, but this single study is insufficient to establish atenolol as preferred therapy. 12
Current guidelines recommend IV nicardipine or other easily titratable calcium channel blockers for acute ICH, targeting systolic BP <140 mmHg with careful monitoring to avoid precipitous drops. 10, 13
Atenolol for Secondary Stroke Prevention
Atenolol is not recommended as first-line therapy for secondary stroke prevention after TIA or ischemic stroke.
Evidence from Secondary Prevention Trials
The Dutch TIA Trial (n=1,473) showed atenolol provided no benefit over placebo for preventing death, stroke, or myocardial infarction in aspirin-treated patients after TIA or minor stroke (adjusted hazard ratio 1.00), despite lowering systolic BP by 5.8 mmHg. 14
The trial showed a non-significant trend toward stroke reduction (hazard ratio 0.82) but was underpowered, and more patients on atenolol reported adverse effects (153 vs 103 on placebo). 14
Preferred Regimen for Secondary Prevention
After the acute phase (>72 hours), the preferred regimen for secondary stroke prevention is an ACE inhibitor plus thiazide diuretic, targeting BP <140/90 mmHg (or <130/80 mmHg for high-risk patients). 7, 15
The PROGRESS trial demonstrated that perindopril plus indapamide reduced recurrent stroke by 43%, establishing the ACE inhibitor/thiazide combination as Grade A evidence for secondary prevention. 15
If ACE inhibitors are not tolerated, substitute an ARB plus thiazide—but never combine ACE inhibitor with ARB, as this increases adverse events without added benefit. 15
Beta-blockers should only be used for secondary prevention when there is a compelling cardiac indication (recent MI, heart failure, angina). 9, 15
Critical Pitfalls to Avoid
Never use atenolol or any oral antihypertensive for acute blood pressure management in the first 72 hours after stroke unless systolic BP ≥220 mmHg or diastolic BP ≥120 mmHg, and even then, use short-acting IV agents. 7, 10, 11
Do not select atenolol as first-line for primary or secondary stroke prevention when thiazides, ACE inhibitors, ARBs, or calcium channel blockers are available and more effective. 7, 8, 15
Avoid beta-blockers in patients with multiple metabolic risk factors (obesity, impaired fasting glucose, metabolic syndrome) as they increase the risk of new-onset diabetes. 6
In elderly patients (>60 years), atenolol is associated with increased stroke risk compared to other antihypertensives and should be avoided. 5